SCHEMBL3759278

SCHEMBL3759278

COc1cccc(C#Cc2c(N3CCOCC3)sc3c2CC(C)(C)CC3=O)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 4/20 0.39
PIK3CG P48736 3/20 0.38
PIK3CD O00329 2/20 0.38
PIK3CB P42338 2/20 0.38
ALDH1A1 P00352 4/20 0.38
HSD17B10 Q99714 3/20 0.38
HPGD P15428 2/20 0.38
GAA P10253 2/20 0.38
KDM4E B2RXH2 1/20 0.38
GLA P06280 1/20 0.38
CYP3A4 P08684 1/20 0.38
CASP1 P29466 1/20 0.38
KLK7 P49862 1/20 0.38
CASP7 P55210 1/20 0.38
RXFP1 Q9HBX9 1/20 0.37
PRKDC P78527 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
GAK O14976 1/20 0.36
MAPT P10636 1/20 0.35
ALOX15 P16050 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3758960 0.88 PIK3CA (0.40) PIK3CAPIK3CGPIK3CDPIK3CBALDH1A1
SCHEMBL16161687 0.87 PIK3CA (0.39) PIK3CAPIK3CGPIK3CDPIK3CBALDH1A1
SCHEMBL3754871 0.86 PIK3CA (0.43) PIK3CAPIK3CGPIK3CDPIK3CBALDH1A1
SCHEMBL3763646 0.81 PIK3CA (0.41) PIK3CAPIK3CGPIK3CDPIK3CBGRM5
SCHEMBL3754814 0.81 PRKDC (0.46) PIK3CAPIK3CGPIK3CDPIK3CBALDH1A1
SCHEMBL3764957 0.81 PIK3CA (0.42) PIK3CAPIK3CGPIK3CDPIK3CBALDH1A1
SCHEMBL3759332 0.81 PIK3CA (0.44) PIK3CAPIK3CGPIK3CDPIK3CBALDH1A1
SCHEMBL3751895 0.79 PIK3CA (0.40) PIK3CAPIK3CGPIK3CDPIK3CBALDH1A1
SCHEMBL3759333 0.79 PIK3CA (0.39) PIK3CAPIK3CGPIK3CDPIK3CBALDH1A1
SCHEMBL3765808 0.79 PIK3CD (0.40) PIK3CAPIK3CGPIK3CDPIK3CBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA PIK3CA 3/4885PIK3CG 12/4885PIK3CD 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.